Evidence map›Paper›PMID 34445428›Full record

ReviewInternational journal of molecular sciences2021

Molecular Hydrogen as a Novel Antitumor Agent: Possible Mechanisms Underlying Gene Expression.

Shin-Ichi Hirano, Haru Yamamoto, Yusuke Ichikawa, Bunpei Sato, Yoshiyasu Takefuji, Fumitake Satoh

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Molecular Hydrogen in the Treatment of Respiratory Diseases.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Prospects of molecular hydrogen in cancer prevention and treatment.Journal of cancer research and clinical oncology · 2024
    Review
  13. Review
  14. Review
  15. Nanoparticles in Medicine: Current Status in Cancer Treatment.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Shin-Ichi HiranoDepartment of Research and Development, MiZ Company Limited, 2-19-15 Ofuna, Kamakura 247-0056, Kanagawa, Japan.ORCID 0000-0002-8610-8922
Haru YamamotoMiZ Inc., 39899 Balentine Drive Suite 200, Newark, CA 94560, USA.
Yusuke IchikawaDepartment of Research and Development, MiZ Company Limited, 2-19-15 Ofuna, Kamakura 247-0056, Kanagawa, Japan.
Bunpei SatoDepartment of Research and Development, MiZ Company Limited, 2-19-15 Ofuna, Kamakura 247-0056, Kanagawa, Japan.
Yoshiyasu TakefujiFaculty of Environment and Information Studies, Keio University (Professor Emeritus), 5322 Endo, Fujisawa 252-0882, Japan.ORCID 0000-0002-1826-742X
Fumitake SatohDepartment of Research and Development, MiZ Company Limited, 2-19-15 Ofuna, Kamakura 247-0056, Kanagawa, Japan.
Musashino University · JPUniversity of California, Berkeley · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While many antitumor drugs have yielded unsatisfactory therapeutic results, drugs are one of the most prevalent therapeutic measures for the treatment of cancer. The development of cancer largely results from mutations in nuclear DNA, as well as from those in mitochondrial DNA (mtDNA). Molecular hydrogen (H

Indexed as

Antineoplastic AgentsClinical Trials as TopicGene Expression Regulation, NeoplasticHumansHydrogenNeoplasmsOxidative StressReactive Oxygen SpeciesAntineoplastic AgentsHydrogenReactive Oxygen Speciesantitumor agentantitumor effectclinical applicationDNA mutationgene expressionmolecular hydrogenoxidative stressreactive oxygen speciesROS

Identifiers

PMID34445428
PMCPMC8395776
OpenAlexW3193852797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.